Stay updated with breaking news from Thomas Theuringer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BLIRT adds new R&D and manufacturing capabilities for customized and standardized recombinant enzymes, as well as molecular biology reagents Strengthens QIAGEN's sample technologies business
Press release content from Business Wire. The AP news staff was not involved in its creation.
Q1 2022: Net sales rise 11% (+15% constant exchange rates, or CER) to $628.4 million vs. outlook for at least 7% CER growth; diluted EPS of $0.67 and adjusted diluted EPS of $0.80 ($0.83 CER) vs.
Element Biosciences, Inc., developer of a new and disruptive DNA sequencing platform, today announced a partnership with QIAGEN to validate its leading NGS library prep and target enrichment offerings
Q4 2021: Net sales grow 2% (+4% constant exchange rates, or CER) to $582 million and adjusted diluted EPS rises 9% to $0.74 ($0.75 CER) both above outlook Full-year 2021: Net sales grow 20%